Danaher raised its full-year earnings forecast after reporting a first-quarter beat driven by double-digit momentum in its Biotechnology and Life Sciences segments. The diagnostics and life-sciences company upgraded the top end of its 2026 adjusted earnings per share guidance to a new range of $8.35 to $8.55, up from $8.35 to $8.50 previously.

Shares ticked up 1.4% to $198.29 in premarket trading on Tuesday. Analysts polled by FactSet expect earnings of $8.40 per share for the year, placing Danaher's revised guidance comfortably above consensus estimates. The company noted core revenue is still expected to grow 3% to 6% year-over-year.\n

The upgrade reflects sustained strength across Danaher's higher-margin biotech and life sciences businesses, which have benefited from continued demand for bioprocessing and drug discovery tools. The company's ability to raise the upper end of its outlook while keeping the bottom end unchanged suggests management sees the momentum as durable rather than transient.